CAR receptor molecules are genetically engineered to activate T lymphocytes and achieve an antitumour response. CAR-T therapy represents a significant advance in cancer treatment, with ongoing research into new therapeutic targets, the most common being CD19 and BCMA. These proteins are crucial for the development and effectiveness of CAR-T therapies, offering new hope for patients with certain types of cancer. At CymitQuimica, we provide a wide range of high-quality CAR-T therapy target proteins to support your research and clinical applications.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.
Please see our Cookies Policy for more details or adjust your preferences in "Settings".
This is the advanced settings system for our own and third-party cookies. Here you can modify parameters that will directly affect your browsing experience on this website. If you wish you may check the list of Cookie types.
Please note that disabling cookies can cause failures in the normal operation of the web.